Medline (MDLN), one of the largest manufacturers and distributors of medical supplies, has officially made its highly anticipated debut on the Nasdaq Global Select Market on Wednesday, December 17, 2025. The launch, which marks the transformation of the company into a publicly traded entity, is considered a milestone moment for both the healthcare sector and global markets.
Investors had been anticipating Medline’s IPO for years, and the company finally decided to go public when the market calmed and institutional investors’ interest in healthcare companies increased. The debut comes after the world’s largest initial public offering (IPO) of 2025, which sold over 216 million shares at $29 apiece for a substantial $6.26 billion.
Medline IPO Backed by Major Firms and Strong Financials
Prominent underwriters like Goldman Sachs, Morgan Stanley, BofA Securities, and J.P. Morgan spearheaded the IPO with assistance from a group of over 40 organizations. The majority of the offering’s proceeds will go into improving the balance sheet and paying down debt, with the remaining funds going toward basic business needs.
As a global medical supplies provider, Medline reported $20.6 billion in revenue and $977 million in net profit for the nine months ending September 27, 2025, showcasing robust financial results. The company offers around 335,000 medical and surgical products, supported by an extensive global supply chain and workforce.
Founded in 1966 by brothers Jon and Jim Mills, the company was acquired in 2021 by Blackstone, Carlyle, and Hellman & Friedman in a $34 billion deal. The Mills family will retain significant voting rights, while the private equity firms will also maintain substantial equity stakes. Analysts see Medline’s successful listing as a potential catalyst for increased large-scale IPOs in 2026, with companies like SpaceX expected to follow.
Impact of Medline’s Nasdaq Debut on the Healthcare IPO Market
The Nasdaq listing and the offering show investor interest in well-established healthcare companies and serve as a benchmark for IPO activity in the industry going forward. The company’s transition from private to public ownership represents a structural shift that may influence governance, reporting, and long-term strategy.
Various market observers note that the company’s move from private to public ownership is an organizational transformation that could have an impact on long-term strategy, reporting, and governance. According to the analysts, the transaction could influence other privately held healthcare companies evaluating public listings, particularly those with mature business models and consistent earnings.
However, other market observers opine that the Nasdaq inclusion could increase the investor scrutiny due to its being subject to regular public disclosures. Market participants are expected to monitor revenue growth, margin performance, and capital allocation decisions in upcoming quarters.
